{"product_id":"demant-pestle-analysis","title":"Demant PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the external forces shaping Demant—political shifts, economic headwinds, tech innovation, and regulatory trends—and turn them into strategic advantage with our concise PESTLE Analysis; ideal for investors and strategists. Purchase the full report for a complete, actionable breakdown ready for immediate use in presentations, valuation models, or strategic plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment-funded systems in Europe and the US VA account for ~35–45% of Demant’s addressable hearing aid volume, directly shaping pricing and unit sales.\u003c\/p\u003e\n\u003cp\u003eReductions in reimbursement rates or public budgets can cut revenues; a 5–10% cut in EU reimbursement could reduce unit ASP-driven revenue by ~€50–150m annually for major suppliers.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025, austerity in parts of the EU has increased competitive tenders, with single-winner bids up 18% year-over-year, pressuring margins and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemant's global supply chain spans Europe, North America and Asia, making it vulnerable to tariffs and non-tariff barriers; in 2024 exports accounted for ~78% of revenue (DKK 18.4bn of DKK 23.6bn), so even modest tariff increases raise COGS materially.\u003c\/p\u003e\n\u003cp\u003eHeightened US–China trade tensions and EU tariff probes can add 3–7% to component costs, prompting relocation to lower-risk sites—Demant reported CAPEX of DKK 1.2bn in 2024 to diversify manufacturing.\u003c\/p\u003e\n\u003cp\u003eStable multilateral trade agreements are critical for Demant’s high‑margin export business: disruptions could compress gross margins from 43% (2024) by several percentage points if export friction persists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical moves toward global regulatory harmonization, such as EU MDR alignment efforts with IMDRF standards, can shorten Demant’s time-to-market and lower compliance costs; harmonization reduced redundant approvals by an estimated 15–20% for medtech firms in 2023–24. \u003c\/p\u003e\n\u003cp\u003eHowever, rising protectionism in some EMs saw 12% more local testing or data-residency demands in 2024, creating market-entry delays and potential revenue impacts for Demant’s expansion strategy. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment campaigns linking hearing loss to dementia—supported by WHO estimates that 1 in 3 dementia cases are attributable to modifiable risks including hearing loss—boost demand for audiological solutions, aiding Demant's market growth.\u003c\/p\u003e\n\u003cp\u003ePolitical backing for school and elderly-care screening increases early adoption; e.g., EU pilots expanded adult hearing screening coverage by ~12% in 2023–24, enhancing device uptake.\u003c\/p\u003e\n\u003cp\u003eCountries that prioritize healthy aging (EU spending on long-term care rose to ~3.5% of GDP in 2024) create favorable procurement and reimbursement environments for Demant.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO: hearing loss linked to dementia risk; 1 in 3 dementia cases modifiable\u003c\/li\u003e\n\u003cli\u003eEU adult hearing screening coverage +12% (2023–24 pilots)\u003c\/li\u003e\n\u003cli\u003eEU long-term care spending ~3.5% of GDP (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTaxation and Corporate Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a Danish-headquartered multinational, Demant faces domestic tax rules plus international frameworks like the OECD Pillar Two global minimum tax (15%), which may affect its effective tax rate—Demant reported an effective tax rate of ~19% in 2024, altering net profit and cash available for reinvestment.\u003c\/p\u003e\n\u003cp\u003eShifts in corporate tax or R\u0026amp;D incentives materially change funding for hearing-technology R\u0026amp;D; Denmark’s R\u0026amp;D tax credit schemes and EU support programs offset costs—Demant’s R\u0026amp;D spend was ~DKK 1.9bn in 2024.\u003c\/p\u003e\n\u003cp\u003eLabor law changes in markets such as the US, Germany and China can raise clinic and manufacturing wage bills; rising labor costs contributed to margin pressures in 2023–24, with adjusted EBIT margin around 8–9% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD Pillar Two 15% impacts ETR vs reported ~19% (2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend ~DKK 1.9bn (2024)\u003c\/li\u003e\n\u003cli\u003eAdjusted EBIT margin ~8–9% (2024) affected by labor cost rises\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemant: Export-led growth, heavy R\u0026amp;D\/CAPEX, 43% gross margin, 8–9% EBIT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment reimbursement, trade barriers and tax rules materially affect Demant’s pricing, margins and capex; 2024 figures: exports 78% (DKK 18.4bn\/23.6bn), gross margin 43%, CAPEX DKK 1.2bn, R\u0026amp;D DKK 1.9bn, ETR ~19%, adjusted EBIT margin 8–9%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports % of rev\u003c\/td\u003e\n\u003ctd\u003e78% (DKK 18.4bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e43%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX\u003c\/td\u003e\n\u003ctd\u003eDKK 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eDKK 1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eETR\u003c\/td\u003e\n\u003ctd\u003e~19%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBIT margin\u003c\/td\u003e\n\u003ctd\u003e8–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how political, economic, social, technological, environmental, and legal forces uniquely affect Demant, with data-driven subpoints and trends tailored to its hearing-health industry and regional markets to inform strategy and risk management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Demant PESTLE summary that’s easily dropped into presentations or shared across teams to accelerate risk discussions and strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising raw material, logistics and labor costs—steel, plastics and semiconductor prices up ~8–12% in 2024—threaten to compress Demant’s 2024 gross margin (FY2023 gross margin 51.4%) unless offset by price increases or productivity gains.\u003c\/p\u003e\n\u003cp\u003eHearing healthcare shows resilience, but persistent inflation pushed EU and US consumer price indices up 5–6% in 2024, risking reduced discretionary spend by private-pay customers for premium devices.\u003c\/p\u003e\n\u003cp\u003eDemant must balance aggressive cost-efficiency measures—OPEX reductions and supply-chain consolidation that cut costs 3–5% in recent initiatives—with preserving quality in manufacturing to avoid warranty and reputation risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemant reports in DKK while roughly 45% of 2024 sales were invoiced in USD and EUR, exposing earnings to FX swings; a 5% DKK appreciation vs USD\/EUR could cut reported revenue by ~2–3%. \u003c\/p\u003e \u003cp\u003eTranslation effects drove a DKK 420m FX loss in 2023, illustrating how exchange-rate moves can materially skew reported profits and equity. \u003c\/p\u003e \u003cp\u003eRobust hedging—forward contracts and currency swaps—remains essential to stabilize EBITDA and protect 2025 cash-flow forecasts against volatile USD\/EUR rates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe rising global interest rate cycle through 2022–24 pushed Demant’s average cost of debt higher, with EURIBOR and US SOFR-based borrowing rates up roughly 250–300 bps, increasing annual interest expenses and weighing on free cash flow for acquisitions. Higher rates raised investor discount rates, pressuring valuation multiples—Demant’s 2024 EV\/EBITDA near 8.5x versus sector averages of ~10x. By late 2025, central bank guidance and easing market expectations signaled stabilization, improving visibility for multi-year capex and M\u0026amp;A financing. Stable rates lower financing costs and reduce hurdle rates for long-term strategic projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA large share of hearing aid sales remains out-of-pocket, with premium devices often purchased directly; in 2024 global hearing aid market revenue reached about USD 9.5bn, and premium segments grew faster than low-end categories.\u003c\/p\u003e\n\u003cp\u003eDuring downturns consumers delay upgrades or choose mid-range models—consumer confidence in EU fell to 93.6 in Dec 2024—pressuring premium sales but boosting volume in lower tiers.\u003c\/p\u003e\n\u003cp\u003eDemant’s multi-tier portfolio, spanning premium to value devices, helps capture demand across segments and reduce revenue volatility; in 2024 Demant reported diversified product mix with ~30% sales from premium lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium-driven out-of-pocket purchases: sizable market share\u003c\/li\u003e\n\u003cli\u003eEconomic downturns reduce upgrades, shift demand to mid-range\u003c\/li\u003e\n\u003cli\u003eDemant’s multi-price portfolio mitigates risk, ~30% premium sales (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic development in Asia-Pacific and Latin America is driving demand for hearing healthcare; Asia-Pacific healthcare spending grew ~6% annually to $2.0 trillion in 2024, and middle‑class households in LATAM rose to ~160 million in 2024, expanding markets for devices and services.\u003c\/p\u003e\n\u003cp\u003eDemant's 2024 annual report shows around 12% of revenue from emerging markets and increased investments in local distribution and clinics to diversify from Europe and North America.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsia‑Pacific healthcare spend ~$2.0T (2024)\u003c\/li\u003e\n\u003cli\u003eLATAM middle class ~160M (2024)\u003c\/li\u003e\n\u003cli\u003eDemant ~12% revenue from emerging markets (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising input, FX and rate pressure shrink margins—hedging and premium mix key\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising input and logistics costs (steel\/plastics\/semiconductors +8–12% in 2024) pressure gross margin (FY2023 51.4%); hedging and price\/efficiency offsets are critical. Inflation (EU\/US CPI 5–6% in 2024) risks dampening premium out‑of‑pocket demand; Demant’s multi-tier mix (~30% premium, 2024) mitigates this. FX exposure (45% sales USD\/EUR) and 2023 DKK 420m FX loss require active hedging; higher rates (EURIBOR\/SOFR +250–300bps) raised financing costs, with 2024 EV\/EBITDA ~8.5x vs sector ~10x.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2023\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost change\u003c\/td\u003e\n\u003ctd\u003e+8–12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e51.4% (FY2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePremium sales\u003c\/td\u003e\n\u003ctd\u003e~30% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX loss\u003c\/td\u003e\n\u003ctd\u003eDKK 420m (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales in USD\/EUR\u003c\/td\u003e\n\u003ctd\u003e~45% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEV\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~8.5x (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eDemant PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Demant PESTLE document you’ll receive after purchase—fully formatted and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the layout, content, and structure visible here are the final file you can download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752095232377,"sku":"demant-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/demant-pestle-analysis.png?v=1772237455","url":"https:\/\/matrixbcg.com\/products\/demant-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}